Jade Biosciences, Inc. - JBIO

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Aug 14, 2026 SCHEDULE 13G/A Venrock Healthcare Capital Partners III, L.P. 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A VHCP Co-Investment Holdings III, LLC 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A Venrock Healthcare Capital Partners EG, L.P. 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A VHCP Management III, LLC 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A VHCP Management EG, LLC 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A Nimish Shah 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A Bong Y. Koh 8.3% 5,145,330 View
Aug 14, 2026 SCHEDULE 13G/A Bellevue Group AG 5.0% 3,057,996 View
Aug 14, 2026 SCHEDULE 13G/A Bellevue Asset Management AG 5.0% 3,057,996 View
Jul 17, 2026 SCHEDULE 13G Paradigm BioCapital Advisors LP 5.1% 3,106,793 View
Jul 17, 2026 SCHEDULE 13G Paradigm BioCapital Advisors GP LLC 5.1% 3,106,793 View
Jul 17, 2026 SCHEDULE 13G Senai Asefaw, M.D. 5.1% 3,106,793 View
Jul 17, 2026 SCHEDULE 13G Paradigm BioCapital International Fund Ltd. 4.5% 2,738,259 View
Jul 08, 2026 SCHEDULE 13G/A JANUS HENDERSON GROUP Ltd. 10.6% 6,273,262 View
Jun 09, 2026 SCHEDULE 13D/A 9.99% View
May 15, 2026 SCHEDULE 13G/A JANUS HENDERSON GROUP PLC 6.3% 3,105,669 View
Apr 27, 2026 SCHEDULE 13G/A BlackRock, Inc. 4.7% 2,295,825 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.